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Abstract
Purpose We report the Wrst case of isolated femur
metastasis in a locally advanced cervical cancer (LACC)
patients.
Case A 40-year-old woman presenting with carcinoma of
the uterine cervix, FIGO stage IIb was administered con-
comitant chemo-radiation and achieved clinical partial
response. Before the planned surgery, she developed an iso-
lated metastatic lytic lesion of the left femur. After surgical
excision of metastasis, she refused palliative chemotherapy,
and radiotherapy, and died 3 months later because of
progression of the disease.
Conclusion Bone metastasis is not so infrequent in
patients with LACC. Because the prognosis of these
patients is poor and most of them die within 1 year after the
diagnosis of metastatic disease, the policy of treatment
should be directed to maintain their quality of life.
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Introduction
Although the incidence of cervical cancer has been reduced
in the developed countries, advanced/recurrent and meta-
static disease remains a major cause of cancer death in
women. Nearly one-third of patients who present with inva-
sive cervical cancer die of the disease [1].
Cervical cancer patients may develop pelvic recur-
rence, distant metastases, or a combination of both.
A 10–20% recurrence rate has been reported following
primary surgery or radiotherapy in women with stage
IB–IIA cervical tumours, while up to 70% of patients
with lymph node metastases or locally advanced tumours
relapse. Bone metastases occurred in 16% of patients,
predominantly involving the lumbar and thoracic
spine, while are uncommon in the distal appendicular
skeleton [2].
We report the Wrst case of bone metastasis from carci-
noma of the cervix, wherein the patient developed isolated
metastasis to left diaphysis femur.
Case report
In August 2007, a 40-year-old fertile woman was admitted
to the Gynaecologic Oncology Unit of the Catholic Univer-
sity of Rome with a diagnosis of a poorly diVerentiated epi-
dermoidal carcinoma of the cervix as documented by
colposcopy-guided biopsy. Her family and gynaecologic
histories were unremarkable.
Gynaecological examination under anaesthesia docu-
mented a uterus of normal size, no adnexal masses; the cer-
vix showed an exoWtic bleeding lesion (3 cm maximum
diameter), with obliteration of anterior, lateral and posterior
fornices. Biopsy was performed and showed the presence
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with adenosquamous type (Fig. 1a).
Staging work-up included chest X-ray, pelvic ultrasono-
graphy (US), and abdomino-pelvic magnetic resonance
imaging (MRI) with contrast. Pelvic US documented the
presence of a cervical lesion (52 £ 27 £ 38 mm) richly
vascularized at color Doppler scan, that appeared to invade
the stroma and the internal uterine oriWce. MRI report
conWrmed the presence of a high-intensity signal area in
T2-weighted images lesion in the cervical canal, antero-
posterior 47 mm, transversal 52 mm and cranio-caudal
33 mm diameter. The left fornix and parametrium were
involved, as well as the superior third of vagina. Bilateral
iliac and inguinal lymph nodes had pericentimetric diame-
ter. Circulating levels of SCC were 2.6 ng/ml; Ca 125
levels were negative (20.5 U/ml).
The patient was staged as having FIGO stage IIB cervical
cancer, and was triaged to concomitant radio-chemotherapy
followed by surgery according to our institutional protocol
[3]. Four weeks after the end of concomitant chemo-
radiotherapy, the patient was evaluated for objective
response. Pelvic MRI documented a partial response of all
dimensions of the cervical lesion, now measuring
15 £ 18 £ 14 mm.
Two weeks before undergoing the planned surgery, she
experienced non-traumatic left diaphysal femur fracture.
MRI of left femur showed a complete pathological fracture
of the femoral diaphyses with relocation of fragments. At
the level of the femur stumps, a voluminous mass involving
the median diaphyses was documented (maximum diameter
9 cm) (Fig. 2).
In order to exclude the presence of breast and lung
cancer, mammography and thorax CT scan were per-
formed. A total body bony scintigraphy was performed and
conWrmed the presence of the femoral lesion only.
On the basis of FDG-PET Wndings, a wide surgical exci-
sion of the lesion was performed and Wnal pathology
revealed the presence of metastasis of poorly diVerentiated
carcinoma of similar morphology as the primary (Fig. 1b).
The surgical margins were free of the disease.
The patient refused palliative chemotherapy and radio-
therapy and after 3 months died because of pulmonary
embolism.
Discussion
The occurrence of bone metastases is considered infre-
quent, likely it is underestimated. Indeed, the rate of the
bone metastases in recurrent cervical carcinoma has been
shown to increase from 15 to 29% [4].
Matsuyama et al. [5] reported that the rates of bone
recurrence, among 713 patients were 4.0% in stage I, 6.6%
in stage II, 8.0% in stage III, and 22.9% in stage IV. The
most frequent site of metastasis was represented by the ver-
tebral column, particularly the lumbar spine (48%) fol-
lowed by the pelvic bones. In 32 cases (67%), bone lesions
Fig. 1 a Primary cervical carcinoma. Poorly diVerentiated tumor cells are arranged in cords (H&E, £200). b Metastatic cervical carcinoma.
Neoplastic cells inWltrate the scheletric muscle and periosteal tissue (H&E, £50)
Fig. 2 T2-weighted MRI showing the presence of a complete patho-
logical fracture of the left femoral diaphyses with a voluminous mass
of caudal skull diameter of about 9 cm123
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treatment, and 36 patients (75%) died within 1 year after
detection of the metastasis.
Spreading to the bone may occur both by direct exten-
sion of the pelvic tumour to the bone, as from soft tissue
metastasis outside the pelvis, and least commonly by hae-
matogenous route.
Establishing the diagnosis of femur metastasis some-
times can be diYcult: indeed, although femur metastases
can be painful or palpable or cause deformity, sometimes
they can be asymptomatic.
Diagnostic imaging techniques are useful tools in order
to deWne the site and extension of the disease, and exclude
diVuse metastases. In our case FDG-PET Wndings were crit-
ical in order to plan patient management, because a diVuse
metastatic disease was excluded and surgical removal of
the femur recurrence could be planned.
Once the bone lesion is diagnosed, the treatment is usu-
ally directed towards both pain relief and preservation of
quality of life considering the patients’ short life expec-
tancy. Given the rare occurrence of bone metastasis, there
are no speciWc guidelines on the therapeutic options, which
can include radiotherapy, chemotherapy, and surgery
according to the clinical setting: indeed, the real beneWt of
these approaches remains questionable given the very poor
prognosis of these patients.
Generally, in case of a solitary and resectable bone
metastasis surgical management followed by palliative
radiotherapy is recommended [6].
We oVered our patient a multimodal approach, consider-
ing her young age and good performance status, and the
documentation of a single and surgically amenable recur-
rence.
The acknowledgement of the femur metastasis as a
marker of systemic disease prompted us to also plan the
administration of chemotherapy: in particular the platinum–
taxane combination was chosen on the basis of the high
response rate documented with this regimen compared to
cisplatin alone [7].
In conclusion, since bone metastasis is not so infrequent,
especially in patients with locally advanced cervical cancer
(LACC), our data conWrm that the total body PET-TC scan
should be included in staging work up as recommended by
the guidelines of the National Comprehensive Cancer
Network (NCCN) [8].
It has to be acknowledged that besides its role in clinical
staging pre-treatment as well as post-chemoradiation total
body PET-CT scan Wndings have been shown to accurately
predict clinical outcome in LACC [9].
Moreover, very recent data on LACC seem to suggest
that PET-CT scan guided treatment can also improve over-
all survival [10].
Additionally, since the prognosis of these patients is dis-
mal, and most of them died within 1 year after diagnosis of
metastatic disease, the policy of treatment should be
directed to maintain their quality of life.
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